Dr Elena De Vita
Lecturer in Synthetic Biology and Biotechnology
Lead for ECR & Research Environment
School of Biological and Behavioural Sciences
Queen Mary University of London
Research
Chemical Biology, Covalent ligands, Induced Proximity, PHOSTACs, Drug Discovery, High throughput screening
Interests
Building on a track-record in covalent drug discovery (The Future of Covalent Drugs, Discovery Report Q3, C&EN, 2022), the De Vita group aims at integrating the advantages of small molecule covalent ligands to advance novel applications in Chemical Biology and Drug Discovery. We are interested in developing novel assays and techniques to discover and optimise small molecule covalent binders for challenging targets, which have potential applications in the rising field of chemically induced proximity. Furthermore, we are constantly on the look for Chemical Biology methodologies that will enable understanding of small molecule and protein function in cells with a translational perspective.
Current research lines are focused on PHOSphorylation TArgeting Chimeras (PHOSTACs), a chemically induced proximity approach that employs bifunctional ligands to recruit a protein phosphatase (PP) in the proximity of a phosphorylated protein of interest to drive targeted protein dephosphorylation. Small molecule PHOSTACs will be developed to uncover the role of the unknown phosphoproteome, which still represents the majority of all known phosphosites profiled in humans to date. Mainly focusing on cancer research, we aim to further study the mechanism of action of PHOSTACs and develop ligands with improved pharmacological properties to explore novel therapeutic opportunities in cancer, where protein hyperphosphorylation is a well-known driver of disease.
Publications

Publications of specific relevance to the Centre for Molecular Cell Biology
2025
Advances in selective targeting of serine hydrolases: A targeted covalent approach against hCES2A mitigates irinotecan toxicity in vivoDe Vita E
Acta Pharmaceutica Sinica B,
Elsevier vol. 15 (10), 5491-5492.
01-10-2025
The phosphate of lifeDe Vita E Page R
Nature Chemistry,
Springer Nature vol. 17 (3), 460-460.
01-03-20252024
What is chemical biology?Antolin AA Aye Y Bar-Peled L De Vita E Dudkina N Jewett MC Kiely-Collins H Mazitschek R et al.
Cell Chemical Biology,
Elsevier vol. 31 (9), 1562-1565.
01-09-2024
Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACsShah RR De Vita E Sathyamurthi PS Conole D Zhang X Fellows E Dickinson ER Fleites CM et al.
Journal of Medicinal Chemistry,
American Chemical Society (Acs) vol. 67 (6), 4641-4654.
13-03-20242022
A KLK6 Activity-Based Probe Reveals a Role for KLK6 Activity in Pancreatic Cancer Cell InvasionZhang L Lovell S De Vita E Jagtap PKA Lucy D Grocin AG Kjær S Borg A et al.
Journal of The American Chemical Society,
American Chemical Society (Acs) vol. 144 (49), 22493-22504.
22-11-2022
Identification of the first structurally validated covalent ligands of the small GTPase RAB27AJamshidiha M Lanyon-Hogg T Sutherell CL Craven GB Tersa M De Vita E Brustur D Pérez-Dorado I et al.
Rsc Medicinal Chemistry,
Royal Society of Chemistry (Rsc) vol. 13 (2), 150-155.
01-01-2022
Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)Zhang Q Kounde CS Mondal M Greenfield JL Baker JR Kotelnikov S Ignatov M Tinworth CP et al.
Chemical Communications,
Royal Society of Chemistry (Rsc) vol. 58 (78), 10933-10936.
01-01-20222021
Blocking Kallikrein 6 promotes developmental myelinationYoon H Triplet EM Simon WL Choi C Kleppe LS De Vita E Miller AK Scarisbrick IA
Glia,
Wiley vol. 70 (3), 430-450.
09-10-2021
Beyond targeted protein degradation: LD·ATTECs clear cellular lipid dropletsDe Vita E Lucy D Tate EW
Cell Research,
Springer Nature vol. 31 (9), 945-946.
05-08-2021
A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate CancerLovell S Zhang L Kryza T Neodo A Bock N De Vita E Williams ED Engelsberger E et al.
Journal of The American Chemical Society,
American Chemical Society (Acs) vol. 143 (23), 8911-8924.
04-06-2021
Development of a fluorogenic ADAMTS-7 substrateSantamaria S Buemi F Nuti E Cuffaro D De Vita E Tuccinardi T Rossello A Howell S et al.
Journal of Enzyme Inhibition and Medicinal Chemistry,
Taylor & Francis vol. 36 (1), 2160-2169.
01-01-20212020
10 years into the resurgence of covalent drugsDe Vita E
Future Medicinal Chemistry,
Taylor & Francis vol. 13 (2), 193-210.
04-12-2020
The Missing Link between (Un)druggable and Degradable KRASDe Vita E Maneiro M Tate EW
Acs Central Science,
American Chemical Society (Acs) vol. 6 (8), 1281-1284.
03-08-20202019
Synthesis and Structure‐Activity Relationships of N‐(4‐Benzamidino)‐Oxazolidinones: Potent and Selective Inhibitors of Kallikrein‐Related Peptidase 6De Vita E Smits N van den Hurk H Beck EM Hewitt J Baillie G Russell E Pannifer A et al.
Chemmedchem,
Wiley vol. 15 (1), 79-95.
18-11-2019
Design and Synthesis of Ionic Liquid‐Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI‐Coated Gold NanoparticlesD'Andrea F Nuti E Becherini S Cuffaro D Husanu E Camodeca C De Vita E Zocchi MR et al.
Chemmedchem,
Wiley vol. 14 (6), 686-698.
14-02-20192018
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular ActivityDe Vita E Schüler P Lovell S Lohbeck J Kullmann S Rabinovich E Sananes A Heßling B et al.
Journal of Medicinal Chemistry,
American Chemical Society (Acs) vol. 61 (19), 8859-8874.
13-09-2018
A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineeringSananes A Cohen I Shahar A Hockla A De Vita E Miller AK Radisky ES Papo N
Journal of Biological Chemistry,
Elsevier vol. 293 (33), 12663-12680.
22-06-2018
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometryLonguespée R Wefers AK De Vita E Miller AK Reuss DE Wick W Herold-Mende C Kriegsmann M et al.
Acta Neuropathologica Communications,
Springer Nature vol. 6 (1)
02-03-2018
Structure-guided design and optimization of covalent VHL-targeted sulfonyl fluoride PROTACsShah RR De Vita E Conole D Sathyamurthi PS Zhang X Fellows E Fleites CM Queisser MA et al.
In
Biorxiv
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugsManeiro M De Vita E Conole D Kounde C Zhang Q Tate E
In
Progress in Medicinal Chemistry,
Elsevier 67-190.
A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancerLovell S Zhang L Kryza T Neodo A Bock N Williams ED Engelsberger E Xu C et al.
In
Biorxiv
Synthesis and Structure–Activity Relationships of N-(4-Benzamidino)-Oxazolidinones–Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6De Vita E Smits N van den Hurk H Beck EM Hewitt J Baillie G Russell E Pannifer A et al.
In
Chemrxiv
Grants

Grants of specific relevance to the Centre for Molecular Cell Biology
Development of covalent probes for protein phosphatase 1 (PP1)Elena De Vita£11,000
Royal Society31-03-2024 - 30-03-2026
Covalent PHOSTACs for targeted protein dephosphorylation against K-Ras driven tumoursElena De Vita£69,401
Royal Society01-03-2024 - 31-08-2025
Research Group
PhD Students
- Hannes Giovanazzi
Directed Evolution of Photosystem II For Light-Driven Biocatalysis - Boman Li
Chemical Biology and Structure-Based Approaches to Study Nov - Kaichen Peng
Structural Studies of Bacterial DNA Replication Initiation Mechanism Using Cryo Electron Microscopy (Cryo-EM) and Novel Antibiotic Discovery - Tara Shutes
Chemical Biology Approaches to Study and Modulate Protein Phosphatases - Kexin Wang
Engineering Ubiquitin Ligases For Targeted Protein Degradation of Cancer-Associated Proteins - Charlotte Woolley
Cell Free Systems For Novel Antibiotics to Counter Antimicrobial Resistance